Sucampo Pharmaceuticals (SCMP) Sees Strong Trading Volume

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) shares saw unusually-strong trading volume on Tuesday . Approximately 26,319,828 shares were traded during trading, an increase of 2,802% from the previous session’s volume of 906,852 shares.The stock last traded at $18.00 and had previously closed at $17.00.

Several equities research analysts have weighed in on SCMP shares. Zacks Investment Research raised Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research report on Tuesday, October 17th. UBS Group dropped their target price on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, October 12th. Maxim Group set a $23.00 target price on Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, December 7th. B. Riley raised their target price on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, December 6th. Finally, BidaskClub upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, December 5th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $21.00.

The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46. The firm has a market cap of $792.81, a price-to-earnings ratio of -5.47, a PEG ratio of 5.06 and a beta of 1.47.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The company had revenue of $61.27 million for the quarter, compared to analysts’ expectations of $58.05 million. During the same period in the previous year, the firm posted $0.30 EPS. Sucampo Pharmaceuticals’s revenue was up 5.9% compared to the same quarter last year. research analysts forecast that Sucampo Pharmaceuticals, Inc. will post 1.12 earnings per share for the current fiscal year.

In related news, insider Peter A. Kiener sold 50,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $16.50, for a total value of $825,000.00. Following the sale, the insider now directly owns 52,023 shares in the company, valued at approximately $858,379.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 4.13% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Krensavage Asset Management LLC lifted its stake in Sucampo Pharmaceuticals by 0.6% in the 2nd quarter. Krensavage Asset Management LLC now owns 2,819,708 shares of the biopharmaceutical company’s stock worth $29,607,000 after purchasing an additional 16,570 shares in the last quarter. LSV Asset Management lifted its stake in Sucampo Pharmaceuticals by 1.9% in the 2nd quarter. LSV Asset Management now owns 2,390,418 shares of the biopharmaceutical company’s stock worth $25,099,000 after purchasing an additional 44,000 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Sucampo Pharmaceuticals in the 3rd quarter worth approximately $21,989,000. Vanguard Group Inc. lifted its stake in Sucampo Pharmaceuticals by 13.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company’s stock worth $17,287,000 after purchasing an additional 189,561 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Sucampo Pharmaceuticals by 1.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company’s stock worth $16,487,000 after purchasing an additional 15,528 shares in the last quarter. 65.29% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Sucampo Pharmaceuticals (SCMP) Sees Strong Trading Volume” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/12/26/sucampo-pharmaceuticals-scmp-sees-strong-trading-volume.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

What are top analysts saying about Sucampo Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sucampo Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit